Thrasos Therapeutics Announces Successful Formal Interim Analysis And Clinical Update For Phase 2 Study Of THR-184 For Acute Kidney Injury

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MONTREAL--(BUSINESS WIRE)--Thrasos Therapeutics, a biotherapeutics company focused on delivering new solutions for kidney disease, today announced that a pre-planned formal interim analysis of 140 subjects enrolled in its Phase 2 clinical study of THR-184 for Acute Kidney Injury (AKI) has been completed. The study will now continue and the dosing strategy will be adjusted based on recommendations of the Independent Data Monitoring Committee (IDMC). At this time 200 subjects have been enrolled in the ongoing clinical trial.

The interim analysis was conducted by an independent statistical team and reviewed with the IDMC. It focused on the safety and efficacy of three original doses of THR-184 compared to placebo. The IDMC recommended continuation of the study based on safety and further recommended that the study proceed using the original high dose arm, dropping the two lower dose arms. Thrasos will continue the study as recommended by the IDMC and will add a higher dose arm, expanding the study to a total of approximately 450 subjects.

Help employers find you! Check out all the jobs and post your resume.

Back to news